Safety of lenalidomide as maintenance therapy after allogeneic hematopoietic stem cell transplantation for multiple myeloma

Trial Profile

Safety of lenalidomide as maintenance therapy after allogeneic hematopoietic stem cell transplantation for multiple myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Oct 2016

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma; Plasma cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top